...
mnkd-img

MannKind Corp, Common Stock

MNKD

NMQ

$6.85

+$0.55

(8.73%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.74B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
78.75
Volume info-icon
This is the total number of shares traded during the most recent trading day.
7.05M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.17 L
$7.63 H
$6.85

About MannKind Corp, Common Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMNKDSectorS&P500
1-Week Return4.74%-2.12%-3%
1-Month Return-0.44%-3.42%-0.73%
3-Month Return3.79%-11.13%2.87%
6-Month Return40.95%-5.74%7.17%
1-Year Return105.4%3.97%25.31%
3-Year Return56.04%1.05%28.38%
5-Year Return396.38%34.37%81.89%
10-Year Return-74.54%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue63.04M65.14M75.44M99.77M198.96M[{"date":"2019-12-31","value":31.68,"profit":true},{"date":"2020-12-31","value":32.74,"profit":true},{"date":"2021-12-31","value":37.92,"profit":true},{"date":"2022-12-31","value":50.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue27.98M24.64M38.86M57.50M62.77M[{"date":"2019-12-31","value":44.57,"profit":true},{"date":"2020-12-31","value":39.26,"profit":true},{"date":"2021-12-31","value":61.9,"profit":true},{"date":"2022-12-31","value":91.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit35.06M40.50M36.59M42.27M136.19M[{"date":"2019-12-31","value":25.74,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":26.86,"profit":true},{"date":"2022-12-31","value":31.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin55.62%62.17%48.49%42.37%68.45%[{"date":"2019-12-31","value":81.25,"profit":true},{"date":"2020-12-31","value":90.83,"profit":true},{"date":"2021-12-31","value":70.85,"profit":true},{"date":"2022-12-31","value":61.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses81.57M65.29M90.07M111.19M125.60M[{"date":"2019-12-31","value":64.95,"profit":true},{"date":"2020-12-31","value":51.98,"profit":true},{"date":"2021-12-31","value":71.71,"profit":true},{"date":"2022-12-31","value":88.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(46.51M)(24.79M)(53.48M)(68.92M)8.68M[{"date":"2019-12-31","value":-535.95,"profit":false},{"date":"2020-12-31","value":-285.61,"profit":false},{"date":"2021-12-31","value":-616.31,"profit":false},{"date":"2022-12-31","value":-794.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(15.30M)(18.85M)(50.37M)(45.55M)(38.76M)[{"date":"2019-12-31","value":-1530200000,"profit":false},{"date":"2020-12-31","value":-1884900000,"profit":false},{"date":"2021-12-31","value":-5036900000,"profit":false},{"date":"2022-12-31","value":-4554600000,"profit":false},{"date":"2023-12-31","value":-3876200000,"profit":false}]
Pre-Tax Income(51.90M)(57.46M)(80.93M)(87.40M)(10.38M)[{"date":"2019-12-31","value":-5190300000,"profit":false},{"date":"2020-12-31","value":-5745800000,"profit":false},{"date":"2021-12-31","value":-8092600000,"profit":false},{"date":"2022-12-31","value":-8740000000,"profit":false},{"date":"2023-12-31","value":-1037700000,"profit":false}]
Income Taxes7.83M(218.00K)10.87M24.77M1.56M[{"date":"2019-12-31","value":31.6,"profit":true},{"date":"2020-12-31","value":-0.88,"profit":false},{"date":"2021-12-31","value":43.87,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.3,"profit":true}]
Income After Taxes(59.73M)(57.24M)(91.79M)(112.17M)(11.94M)[{"date":"2019-12-31","value":-5972900000,"profit":false},{"date":"2020-12-31","value":-5724000000,"profit":false},{"date":"2021-12-31","value":-9179100000,"profit":false},{"date":"2022-12-31","value":-11216900000,"profit":false},{"date":"2023-12-31","value":-1193800000,"profit":false}]
Income From Continuous Operations(51.90M)(57.24M)(80.93M)(87.40M)(31.29M)[{"date":"2019-12-31","value":-5190300000,"profit":false},{"date":"2020-12-31","value":-5724000000,"profit":false},{"date":"2021-12-31","value":-8092600000,"profit":false},{"date":"2022-12-31","value":-8740000000,"profit":false},{"date":"2023-12-31","value":-3128600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(59.73M)(57.24M)(91.79M)(112.17M)(11.94M)[{"date":"2019-12-31","value":-5972900000,"profit":false},{"date":"2020-12-31","value":-5724000000,"profit":false},{"date":"2021-12-31","value":-9179100000,"profit":false},{"date":"2022-12-31","value":-11216900000,"profit":false},{"date":"2023-12-31","value":-1193800000,"profit":false}]
EPS (Diluted)(0.27)(0.20)(0.23)(0.34)(0.05)[{"date":"2019-12-31","value":-27,"profit":false},{"date":"2020-12-31","value":-20,"profit":false},{"date":"2021-12-31","value":-23,"profit":false},{"date":"2022-12-31","value":-34,"profit":false},{"date":"2023-12-31","value":-4.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MNKD
Cash Ratio 3.49
Current Ratio 4.54
Quick Ratio 4.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MNKD
ROA (LTM) 9.12%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MNKD
Debt Ratio Lower is generally better. Negative is bad. 1.45
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.45

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MNKD
Trailing PE 78.75
Forward PE 34.97
P/S (TTM) 6.50
P/B 0.00
Price/FCF 220
EV/R 6.10
EV/Ebitda 23.69
PEG NM

FAQs

What is MannKind Corp share price today?

MannKind Corp (MNKD) share price today is $6.85

Can Indians buy MannKind Corp shares?

Yes, Indians can buy shares of MannKind Corp (MNKD) on Vested. To buy MannKind Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNKD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MannKind Corp be purchased?

Yes, you can purchase fractional shares of MannKind Corp (MNKD) via the Vested app. You can start investing in MannKind Corp (MNKD) with a minimum investment of $1.

How to invest in MannKind Corp shares from India?

You can invest in shares of MannKind Corp (MNKD) via Vested in three simple steps:

  • Click on Sign Up or Invest in MNKD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in MannKind Corp shares
What is MannKind Corp 52-week high and low stock price?

The 52-week high price of MannKind Corp (MNKD) is $7.63. The 52-week low price of MannKind Corp (MNKD) is $3.17.

What is MannKind Corp price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of MannKind Corp (MNKD) is 78.75

What is MannKind Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MannKind Corp (MNKD) is 0.00

What is MannKind Corp dividend yield?

The dividend yield of MannKind Corp (MNKD) is 0.00%

What is the Market Cap of MannKind Corp?

The market capitalization of MannKind Corp (MNKD) is $1.74B

What is MannKind Corp’s stock symbol?

The stock symbol (or ticker) of MannKind Corp is MNKD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top